Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cronos Group Inc. stock logo
CRON
Cronos Group
$2.50
-1.2%
$2.24
$1.60
$2.77
$969.09M1.134.22 million shs2.36 million shs
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
$10.77
+1.6%
$10.39
$3.90
$14.67
$1.03B1.63745,203 shs928,069 shs
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$16.99
+1.1%
$16.39
$10.91
$40.26
$1.02B2.87406,222 shs672,557 shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$1.93
-3.5%
$2.06
$0.13
$3.29
$244.50M2.057.73 million shs4.78 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cronos Group Inc. stock logo
CRON
Cronos Group
+1.20%-1.17%+25.25%+32.46%+12.95%
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
+2.12%+3.31%+8.83%+15.72%+5.26%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
+1.08%-1.93%+4.02%+1.14%-36.80%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-1.96%0.00%-5.21%+794.45%+140.01%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cronos Group Inc. stock logo
CRON
Cronos Group
$2.50
-1.2%
$2.24
$1.60
$2.77
$969.09M1.134.22 million shs2.36 million shs
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
$10.77
+1.6%
$10.39
$3.90
$14.67
$1.03B1.63745,203 shs928,069 shs
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$16.99
+1.1%
$16.39
$10.91
$40.26
$1.02B2.87406,222 shs672,557 shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$1.93
-3.5%
$2.06
$0.13
$3.29
$244.50M2.057.73 million shs4.78 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cronos Group Inc. stock logo
CRON
Cronos Group
+1.20%-1.17%+25.25%+32.46%+12.95%
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
+2.12%+3.31%+8.83%+15.72%+5.26%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
+1.08%-1.93%+4.02%+1.14%-36.80%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-1.96%0.00%-5.21%+794.45%+140.01%
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cronos Group Inc. stock logo
CRON
Cronos Group
$117.61M8.14$0.00 per share5,437.12$2.90 per share0.86
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
N/AN/AN/AN/A$3.45 per shareN/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$890K1,153.03N/AN/A$7.04 per share2.41
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cronos Group Inc. stock logo
CRON
Cronos Group
$41.08M$0.0550.0083.33N/A14.19%-3.78%-3.62%11/11/2025 (Estimated)
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
-$127.85M-$1.890.00N/AN/AN/A-51.75%-47.09%11/11/2025 (Estimated)
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$208.02M-$3.40N/AN/AN/AN/A-71.30%-38.69%11/6/2025 (Estimated)
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/A-$13.66N/AN/AN/AN/AN/AN/AN/A

Latest VOR, SYRE, CRON, and ORIC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
-$0.46-$0.47-$0.01-$0.47N/AN/A
8/7/2025Q2 2025
Cronos Group Inc. stock logo
CRON
Cronos Group
-$0.02-$0.10-$0.08-$0.10$45.73 million$33.46 million
8/5/2025Q2 2025
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$0.73-$0.49+$0.24-$0.49N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cronos Group Inc. stock logo
CRON
Cronos Group
N/AN/AN/AN/AN/A
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
N/AN/AN/AN/AN/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/AN/AN/AN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cronos Group Inc. stock logo
CRON
Cronos Group
N/A
24.65
23.53
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
N/A
16.13
16.13
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/A
6.49
6.49
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Cronos Group Inc. stock logo
CRON
Cronos Group
8.71%
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
95.05%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
80.39%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
97.29%

Insider Ownership

CompanyInsider Ownership
Cronos Group Inc. stock logo
CRON
Cronos Group
7.30%
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
6.82%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
15.43%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
0.45%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cronos Group Inc. stock logo
CRON
Cronos Group
450383.04 million355.08 millionOptionable
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
8097.12 million90.50 millionOptionable
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
7360.40 million51.08 millionOptionable
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
140126.68 million65.45 millionNot Optionable

Recent News About These Companies

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel
Vor Bio to Participate in Upcoming Investor Conferences

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cronos Group stock logo

Cronos Group NASDAQ:CRON

$2.50 -0.03 (-1.19%)
Closing price 04:00 PM Eastern
Extended Trading
$2.50 +0.00 (+0.20%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Oric Pharmaceuticals stock logo

Oric Pharmaceuticals NASDAQ:ORIC

$10.77 +0.17 (+1.60%)
Closing price 04:00 PM Eastern
Extended Trading
$10.45 -0.32 (-2.97%)
As of 06:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Spyre Therapeutics stock logo

Spyre Therapeutics NASDAQ:SYRE

$16.99 +0.18 (+1.07%)
Closing price 04:00 PM Eastern
Extended Trading
$16.72 -0.27 (-1.62%)
As of 04:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Vor Biopharma stock logo

Vor Biopharma NYSE:VOR

$1.93 -0.07 (-3.50%)
Closing price 04:00 PM Eastern
Extended Trading
$1.96 +0.03 (+1.30%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.